Abstract-Vascular endothelial growth factor (VEGF) induces hypotension in normotensive subjects, which is considered to be a major side effect for treatment of ischemic diseases. However, the hypotensive effect of VEGF has not been investigated in the setting of hypertension. This study determined effects of VEGF on hemodynamics, pharmacokinetics, and release of NO and prostaglandin I 2 (PGI 2 ) in vivo and on vasorelaxation of mesentery artery rings in vitro in spontaneously hypertensive rats (SHR) compared with Wistar-Kyoto rats (WKY). Intravenous infusion of VEGF for 2 hours produced a dose-related decrease in arterial pressure, which was enhanced in conscious SHR compared with WKY (PϽ0.01), and an increase in heart rate in WKY but not in SHR. In response to similar doses of VEGF, compared with WKY, SHR had a higher plasma VEGF level and lower VEGF clearance (PϽ0.01). Circulating NO and PGI 2 levels after VEGF administration were not increased in SHR versus WKY, and VEGF-induced vasorelaxation was blunted in SHR versus WKY in vitro, suggesting endothelial dysfunction in SHR. One-week VEGF infusion also caused greater hypotension (PϽ0.05) in the absence of tachycardia in SHR compared with WKY controls. Thus, despite blunted vasorelaxation in vitro because of endothelial dysfunction, SHR exhibited exaggerated hypotension without tachycardia in response to VEGF, which was independent of NO and PGI 2 . The exaggerated hypotensive response to VEGF in SHR may be owing to impaired baroreflex function and reduced VEGF clearance. The data may also suggest that more caution should be taken when VEGF is administered in patients with hypertension. Key Words: growth substances Ⅲ rats, spontaneously hypertensive Ⅲ hemodynamics Ⅲ hypotension Ⅲ blood pressure V ascular endothelial growth factor (VEGF) is a unique mitogen specific for vascular endothelial cells. [1][2][3][4] As a fundamental mediator of normal and pathological angiogenesis, VEGF has been shown to induce a strong angiogenic response in vitro 5,6 and in vivo. 2,3,[7][8][9] Animal studies have demonstrated that administration of VEGF produces beneficial angiogenic effects in peripheral vascular ischemia 10 -12 and in coronary ischemia. [13][14][15][16] VEGF has been shown to induce endothelium-dependent vasorelaxation in normal animals in vitro. [17][18][19] Because of its vasodilatory effect, VEGF induces hypotensive and tachycardic responses in vivo in normotensive animals, including rats, rabbits, and pigs, 14,21 and the hypotensive effect is mediated, at least in part, by NO. 20,21 In humans, intracoronary administration of VEGF caused a hypotensive effect that was dependent on VEGF infusion rate. 22 Although hypotensive effects of VEGF have been characterized in normotensive subjects, these effects have not been investigated in the setting of hypertension.Our previous studies have demonstrated that VEGF induces endothelium-dependent vasorelaxation in aortic rings in vitro, which is diminished in spontaneously hypertensive rats (SHR) compared with normoten...